PURE Bioscience EBIT

As of the most recent data (April 2026), PURE shows a EBIT of $-1.8M. That compares with $-2.6M in the prior-year period — up 29.2% year over year. That is above the sector sector average of $-63M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PURE's EBIT is now $-1.8M (was $-2.6M) — a 29.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether PURE Bioscience is outperforming or lagging.

The its sector sector average EBIT is about $-63M. PURE Bioscience is at $-1.8M, which is higher that average. That is roughly 97.1% above the sector mean. Use the comparison chart on this page to see how PURE stacks up against individual peers as well.

Tracking PURE's ebit over time shows whether PURE Bioscience is scaling, shrinking, or reshaping that part of the business. The current reading is $-1.8M That compares with $-2.6M in the prior-year period — up 29.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has PURE Bioscience's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-1.8M) with ownership activity and broader fundamentals.